Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Finckh

Showing results (211-220 of 225) with videos related to

Pageof 23
Sort By:
Rheumatology (Oxford, England)|November 30, 2014
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registersLianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, et al.
Annals of the Rheumatic Diseases|January 6, 2018
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritisHelga Radner, Katerina Chatzidionysiou, Elena Nikiphorou, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
RMD Open|February 11, 2026
Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysisSumera Qureshi, Maryam Adas, Phoebe J Cope, et al.
BMJ Open|December 15, 2025
Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trialsMaja Skov Kragsnaes, Benoit Thomas P Gilbert, Bjørk Khaliqi Sofíudóttir, et al.
Pageof 23

Showing results (211-220 of 225) with videos related to

Sort By:
Pageof 23
Rheumatology (Oxford, England)|November 30, 2014
The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registersLianne Kearsley-Fleet, Jakub Závada, Merete Lund Hetland, et al.
Annals of the Rheumatic Diseases|January 6, 2018
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritisHelga Radner, Katerina Chatzidionysiou, Elena Nikiphorou, et al.
Annals of the Rheumatic Diseases|June 15, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaborationKim Lauper, Michele Iudici, Denis Mongin, et al.
Annals of the Rheumatic Diseases|December 31, 2024
2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Kim Lauper, Juan Molina-Collada, et al.
Annals of the Rheumatic Diseases|December 10, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)Romain Aymon, Denis Mongin, Sytske Anne Bergstra, et al.
Annals of the Rheumatic Diseases|February 1, 2025
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|December 31, 2024
Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancerEden Sebbag, Juan Molina-Collada, Ramatoulaye Ndoye, et al.
Annals of the Rheumatic Diseases|March 6, 2012
EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid ArthritisDanielle M Gerlag, Karim Raza, Lisa G M van Baarsen, et al.
RMD Open|February 11, 2026
Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysisSumera Qureshi, Maryam Adas, Phoebe J Cope, et al.
BMJ Open|December 15, 2025
Efficacy and safety of microbiota-targeted therapeutics in autoimmune and inflammatory rheumatic diseases: protocol for a systematic review and meta-analysis of randomised controlled trialsMaja Skov Kragsnaes, Benoit Thomas P Gilbert, Bjørk Khaliqi Sofíudóttir, et al.
Pageof 23